Literature DB >> 17655596

HPA-13bw neonatal alloimmune thrombocytopenia and low frequency alloantigens: case report and review of the literature.

Gerald Bertrand1, Frederic Bianchi, Marie Alexandre, Jeannine Quesne, Christophe Chenet, Corinne Martageix, Vincent Jallu, Cecile Kaplan.   

Abstract

BACKGROUND: Fetal-neonatal alloimmune thrombocytopenia (FNAIT) linked to rare or private antigens is not a rare event. STUDY DESIGN AND METHODS: Such a case discovered during the follow-up of a second child with jaundice with mild thrombocytopenia is reported here. Platelet (PLT) genotyping was performed by polymerase chain reaction (PCR)-sequence-specific primers method and PCR-restriction fragment length polymorphism (RFLP) analysis. Serologic investigation was done with the monoclonal antibody-specific immobilization of PLT antigens technique. Glycoprotein Ia-specific amplification and sequencing were performed for the polymorphism 807 (exon 7).
RESULTS: The mother was found to be HPA-13aaw, and the father HPA-13abw. A maternal alloantibody directed against HPA-13bw has been characterized, leading to the diagnosis of neonatal alloimmune thrombocytopenia.
CONCLUSION: This report provides further evidence that NAIT associated with low-frequency antigens is not restricted to single families. Therefore, laboratory investigation of a suspected case should be carried out in a specialist laboratory well experienced in optimal testing to propose appropriate management for the index case and subsequent pregnancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655596     DOI: 10.1111/j.1537-2995.2007.01291.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  1 in total

1.  New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia.

Authors:  Julie A Peterson; Shannon M Pechauer; Maria L Gitter; Adam Kanack; Brian R Curtis; Jeff Reese; Vasudeva M Kamath; Janice G McFarland; Richard H Aster
Journal:  Transfusion       Date:  2011-11-09       Impact factor: 3.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.